Phosphoramidon Disodium Salt
(Synonyms: 磷酰胺二钠) 目录号 : GC16768An inhibitor of NEP and NEP2
Cas No.:164204-38-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
ECs isolated from fresh porcine thoracic aortas |
|
Preparation method |
The solubility of this compound in DMSO is >10mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
10- 7-10-4 M |
|
Applications |
In ECs, phosphoramidon (10- 7-10-4 M) suppressed dose-dependently the apparent converting activity of the membrane fraction and suppressed the membrane fraction induced apparent conversion of big ET-l to ET-l ( Endothelin-1 ). ET-l is a 21 amino acid peptide isolated from the culture medium of vascular endothelial cells (ECs), the secretion of ET-l from cultured ECs was abolished by the addition of phosphoramidon. |
| Animal experiment [2]: | |
|
Animal models |
Wild-type mice, NEP/NEP2-deficient mice |
|
Dosage form |
24 μl (30 mM) once per day for 5 days. |
|
Application |
Intranasal administration of phosphoramidon produced significantly elevated cerebral Aβ (Beta-amyloid peptide) levels in wild-type mice. In NEP/NEP2-deficient mice, Aβ levels were significantly elevated by phosphoramidon, in the absence of NEP (Aβ degrading enzymes) and NEP2, phosphoramidon clearly elevates Aβ1–40 levels relative to Aβ1–42 levels. NEP and NEP2 may be the major “NEP-like” Aβ1–42-degrading (phosphoramidon-sensitive) enzymes in the rodent brain. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Matsumura Y, Ikegawa R, Hisaki K., et al. Conversion of big endothelin-1 to endothelin-1 by phosphoramidon-sensitive metalloproteinase derived from aortic endothelial cells. J Cardiovasc Pharmacol, 1991, 17 Suppl 7: S65-7. [2] . Hanson LR., et al. Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice.J MolNeurosci. 2011 Mar;43(3):424-7. |
|
Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1].
Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.
Phosphoramidon Disodium Salt is a potent metalloproteinase inhibitor. In porcine aortic endothelial cells, phosphoramidon (10-4 M) inhibited immunoreactive-endothelin (IR-ET) release by 10-20% and increased IR-CTF levels. These results suggested that phosphoramidon reduced the IR-ET release through affecting the conversion of big ET-1 to ET-l [1]. In cultured endothelial cells, phosphoramidon inhibited the increase of ET-1 and C-terminal fragment (CTF) of big ET-1. However, phosphoramidon increased big ET-1 secretion [2].
In anesthetized rats, phosphoramidon inhibited the hypertensive effect of big ET-1 [2]. In mice, phosphoramidon inhibited big ET-1 induced lethality and increased plasma IR-ET-1 through inhibition of the enzyme that converted big ET-1 to ET-1 [3].
References:
[1]. Ikegawa R, Matsumura Y, Tsukahara Y, et al. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem Biophys Res Commun, 1990, 171(2): 669-675.
[2]. Matsumura Y, Ikegawa R, Hisaki K, et al. Conversion of big endothelin-1 to endothelin-1 by phosphoramidon-sensitive metalloproteinase derived from aortic endothelial cells. J Cardiovasc Pharmacol, 1991, 17 Suppl 7: S65-7.
[3]. Matsuura A, Okumura H, Ashizawa N, et al. Big endothelin-1-induced sudden death is inhibited by phosphoramidon in mice. Life Sci, 1992, 50(21): 1631-1638.
| Cas No. | 164204-38-0 | SDF | |
| 别名 | 磷酰胺二钠 | ||
| 化学名 | sodium (S)-3-(1H-indol-3-yl)-2-((S)-4-methyl-2-((oxido(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phosphoryl)amino)pentanamido)propanoate | ||
| Canonical SMILES | O=C([O-])[C@@H](NC([C@@H](NP(O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)([O-])=O)CC(C)C)=O)CC2=CNC3=C2C=CC=C3.[Na+].[Na+] | ||
| 分子式 | C23H34N3O10P • 2Na | 分子量 | 589.5 |
| 溶解度 | 14mg/mL in DMSO; 10 mg/ml in DMF; PBS (pH 7.2): 10 mg/ml | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6964 mL | 8.4818 mL | 16.9635 mL |
| 5 mM | 0.3393 mL | 1.6964 mL | 3.3927 mL |
| 10 mM | 0.1696 mL | 0.8482 mL | 1.6964 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。